2022
Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis
Brasky T, Hade E, Cohn D, Newton A, Petruzella S, O'Connell K, Bertrand K, Cook L, De Vivo I, Du M, Freudenheim J, Friedenreich C, Goodman M, Gorzelitz J, Ibiebele T, Krogh V, Liao L, Lipworth L, Lu L, McCann S, O'Mara T, Palmer J, Ponte J, Prizment A, Risch H, Sandin S, Schouten L, Setiawan V, Shu X, Trabert B, van den Brandt P, Webb P, Wentzensen N, Wilkens L, Wolk A, Yu H, Neuhouser M. Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis. Gynecologic Oncology 2022, 169: 137-146. PMID: 36934308, PMCID: PMC10025515, DOI: 10.1016/j.ygyno.2022.10.015.Peer-Reviewed Original ResearchMeSH KeywordsDietEndometrial NeoplasmsFatty Acids, Omega-3FemaleHumansLogistic ModelsObesityOverweightProspective StudiesRisk FactorsConceptsEndometrial cancer riskEndometrial Cancer ConsortiumHigh dietary intakeCancer riskDietary intakeObese womenOdds ratioCancer ConsortiumDietary omega-3 fatty acidsOmega-3 fatty acidsEnergy-adjusted quartilesEndometrial cancer casesEndometrial cancer incidenceProspective cohort studyFood frequency questionnaireNormal-weight womenFatty acid intakeAdjusted odds ratioBody mass indexLong-chain omega-3Anti-inflammatory propertiesSubgroup of womenConfidence intervalsCase-control studyTwo-stage individual participant data
2018
rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology
Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G, Group O, Fasching PA, Beckmann MW, Ekici AB, Hein A, Lambrechts D, Lambrechts S, Van Nieuwenhuysen E, Vergote I, Rossing MA, Doherty JA, Chang-Claude J, Behrens S, Moysich KB, Cannioto R, Lele S, Odunsi K, Goodman MT, Shvetsov YB, Thompson PJ, Wilkens LR, Dörk T, Antonenkova N, Bogdanova N, Hillemanns P, Runnebaum IB, du Bois A, Harter P, Heitz F, Schwaab I, Butzow R, Pelttari LM, Nevanlinna H, Modugno F, Edwards RP, Kelley JL, Ness RB, Karlan BY, Lester J, Orsulic S, Walsh C, Kjaer SK, Jensen A, Cunningham JM, Vierkant RA, Giles GG, Bruinsma F, Southey MC, Hildebrandt MAT, Liang D, Lu K, Wu X, Sellers TA, Levine DA, Schildkraut JM, Iversen ES, Terry KL, Cramer DW, Tworoger SS, Poole EM, Bandera EV, Olson SH, Orlow I, Thomsen L, Bjorge L, Krakstad C, Tangen IL, Kiemeney LA, Aben KKH, Massuger LFAG, van Altena AM, Pejovic T, Bean Y, Kellar M, Cook LS, Le ND, Brooks-Wilson A, Gronwald J, Cybulski C, Jakubowska A, Lubiński J, Wentzensen N, Brinton LA, Lissowska J, Hogdall E, Engelholm SA, Hogdall C, Lundvall L, Nedergaard L, Pharoah PDP, Dicks E, Song H, Tyrer JP, McNeish I, Siddiqui N, Carty K, Glasspool R, Paul J, Campbell IG, Eccles D, Whittemore AS, McGuire V, Rothstein JH, Sieh W, Narod SA, Phelan CM, McLaughlin JR, Risch HA, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Gentry-Maharaj A, Ramus SJ, Wu AH, Pearce CL, Lee AW, Pike MC, Kupryjanczyk J, Podgorska A, Plisiecka-Halasa J, Sawicki W, Goode EL, Berchuck A, Consortium O. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal Of Molecular Sciences 2018, 19: 2473. PMID: 30134598, PMCID: PMC6163881, DOI: 10.3390/ijms19092473.Peer-Reviewed Original ResearchAdenocarcinoma, MucinousCase-Control StudiesFemaleGene Expression Regulation, NeoplasticGenetic Association StudiesHumansHydro-LyasesLogistic ModelsMiddle AgedOdds RatioOvarian NeoplasmsPolymorphism, Single NucleotideProteinsQuantitative Trait LociRiskRNA, AntisenseSignal TransductionThymidylate SynthasePolycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium
Harris HR, Babic A, Webb PM, Nagle CM, Jordan SJ, Group O, Risch H, Rossing M, Doherty J, Goodman M, Modugno F, Ness R, Moysich K, Kjær S, Høgdall E, Jensen A, Schildkraut J, Berchuck A, Cramer D, Bandera E, Wentzensen N, Kotsopoulos J, Narod S, Phelan C, McLaughlin J, Anton-Culver H, Ziogas A, Pearce C, Wu A, Terry K, Consortium O. Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2018, 27: 174-182. PMID: 29141849, PMCID: PMC5877463, DOI: 10.1158/1055-9965.epi-17-0655.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerPolycystic ovary syndromeOvarian cancer riskMenstrual cycle lengthOvarian cancerCancer riskDecreased riskSelf-reported polycystic ovary syndromeLogistic regressionCycle lengthStudy-specific ORsIrregular menstrual cyclesSerous borderline tumorsRisk factor associationsCase-control studyOvarian cancer histotypesPolytomous logistic regressionMucinous tumorsOvary syndromeBorderline tumorsHistologic subtypeOvarian diseaseMenstrual cycleCancer histotypesHistotype
2017
Determining Risk of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants
Dong J, Buas MF, Gharahkhani P, Kendall BJ, Onstad L, Zhao S, Anderson LA, Wu AH, Ye W, Bird NC, Bernstein L, Chow WH, Gammon MD, Liu G, Caldas C, Pharoah PD, Risch HA, Iyer PG, Reid BJ, Hardie LJ, Lagergren J, Shaheen NJ, Corley DA, Fitzgerald RC, consortium S, Whiteman DC, Vaughan TL, Thrift AP. Determining Risk of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. Gastroenterology 2017, 154: 1273-1281.e3. PMID: 29247777, PMCID: PMC5880715, DOI: 10.1053/j.gastro.2017.12.003.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaArea Under CurveAustraliaBarrett EsophagusCase-Control StudiesDatabases, FactualDecision Support TechniquesEsophageal NeoplasmsEuropeFemaleGene-Environment InteractionGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansLife StyleLogistic ModelsMaleMiddle AgedModels, GeneticMolecular EpidemiologyMultifactorial InheritanceNorth AmericaOdds RatioPhenotypePolymorphism, Single NucleotidePredictive Value of TestsRisk AssessmentRisk FactorsROC CurveConceptsGastroesophageal reflux diseaseBarrett's esophagusEsophageal adenocarcinomaLifestyle factorsPolygenic risk scoresGERD symptomsNon-genetic factorsDemographic/lifestyle factorsNet reclassification improvementCharacteristic curve analysisAUC valuesRisk prediction modelEsophageal cancer studyInternational Barrett'sReflux diseaseHighest quartileNet reclassificationEpidemiologic factorsReclassification improvementLowest quartileHigh riskRisk scorePatientsEsophagusAbstractTextA pooled analysis of dietary sugar/carbohydrate intake and esophageal and gastric cardia adenocarcinoma incidence and survival in the USA
Li N, Petrick JL, Steck SE, Bradshaw PT, McClain KM, Niehoff NM, Engel LS, Shaheen NJ, Risch HA, Vaughan TL, Wu AH, Gammon MD. A pooled analysis of dietary sugar/carbohydrate intake and esophageal and gastric cardia adenocarcinoma incidence and survival in the USA. International Journal Of Epidemiology 2017, 46: 1836-1846. PMID: 29040685, PMCID: PMC5837717, DOI: 10.1093/ije/dyx203.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBlood GlucoseBody Mass IndexCase-Control StudiesDietary CarbohydratesDietary SucroseEsophageal NeoplasmsFemaleGastroesophageal RefluxHumansIncidenceLogistic ModelsMaleMiddle AgedMultivariate AnalysisNutrition AssessmentProportional Hazards ModelsRisk FactorsStomach NeoplasmsUnited StatesConceptsGastro-esophageal reflux diseaseBody mass indexCarbohydrate intakeAdenocarcinoma incidenceGCA incidenceOdds ratioUS population-based case-control studyStudy-specific food-frequency questionnairesPopulation-based case-control studyCox proportional hazards regressionGlycaemic indexDietary glycaemic indexFood frequency questionnaireProportional hazards regressionCase-control studyIntake of sucroseHigh glycaemic indexCarbohydrate measuresFrequency questionnaireHazard ratioReflux diseaseMass indexHazards regressionVital statusPooled analysisAspirin Use and Reduced Risk of Pancreatic Cancer
Risch HA, Lu L, Streicher SA, Wang J, Zhang W, Ni Q, Kidd MS, Yu H, Gao YT. Aspirin Use and Reduced Risk of Pancreatic Cancer. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 68-74. PMID: 27999143, PMCID: PMC5225096, DOI: 10.1158/1055-9965.epi-16-0508.Peer-Reviewed Original ResearchConceptsPancreatic cancerAspirin useRegular useConfidence intervalsLong-term aspirin useControl subjects frequencyLow-dose aspirinAvoidance of smokingBody mass indexPopulation-based studyUnconditional logistic regressionABO blood groupRisk-benefit analysisAspirin typeCagA seropositivityDiabetes mellitusMass indexCigarette smokingCardiovascular diseaseAspirinCancerCertain cancersLogistic regressionBlood groupSubjects frequency
2016
Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case–control study
Kho PF, Fawcett J, Fritschi L, Risch H, Webb PM, Whiteman DC, Neale RE. Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case–control study. Cancer Causes & Control 2016, 27: 1457-1464. PMID: 27817122, DOI: 10.1007/s10552-016-0824-4.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsUse of NSAIDsPopulation-based case-control studyCase-control studyAnti-inflammatory drugsPancreatic cancerProtective effectHistory of NSAIDsUnconditional multivariable logistic regressionSelective COX-2 inhibitorsMultivariable logistic regressionPancreatic cancer riskSex-matched controlsCOX-2 inhibitorsPancreatic cancer studiesStatin useMedication useSmoking statusCancer riskMedication sectionStatinsCancerLogistic regressionMore frequent usersCancer studiesMenstrual and Reproductive Factors, Hormone Use, and Risk of Pancreatic Cancer
Lujan-Barroso L, Zhang W, Olson SH, Gao YT, Yu H, Baghurst PA, Bracci PM, Bueno-de-Mesquita H, Foretová L, Gallinger S, Holcatova I, Janout V, Ji BT, Kurtz RC, La Vecchia C, Lagiou P, Li D, Miller AB, Serraino D, Zatonski W, Risch HA, Duell EJ. Menstrual and Reproductive Factors, Hormone Use, and Risk of Pancreatic Cancer. Pancreas 2016, 45: 1401-1410. PMID: 27088489, PMCID: PMC5065728, DOI: 10.1097/mpa.0000000000000635.Peer-Reviewed Original ResearchMeSH KeywordsCase-Control StudiesFemaleHumansLogistic ModelsOdds RatioPancreatic NeoplasmsRisk FactorsConceptsHormone replacement therapyPancreatic cancerHRT useOdds ratioReproductive factorsInternational Pancreatic Cancer Case-Control ConsortiumRisk of PCLarge pooled analysisPancreatic Cancer Case-Control ConsortiumConfidence intervalsCase-control studySignificant inverse associationLogistic regression modelsPostmenopausal womenHormone useControl womenReplacement therapyPooled analysisInverse associationHysterectomyPooled estimatesRelevant covariatesExogenous hormonesWomenRiskRisk Prediction for Epithelial Ovarian Cancer in 11 United States–Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci
Clyde MA, Weber R, Iversen ES, Poole EM, Doherty JA, Goodman MT, Ness RB, Risch HA, Rossing MA, Terry KL, Wentzensen N, Whittemore AS, Anton-Culver H, Bandera EV, Berchuck A, Carney ME, Cramer DW, Cunningham JM, Cushing-Haugen KL, Edwards RP, Fridley BL, Goode EL, Lurie G, McGuire V, Modugno F, Moysich KB, Olson SH, Pearce CL, Pike MC, Rothstein JH, Sellers TA, Sieh W, Stram D, Thompson PJ, Vierkant RA, Wicklund KG, Wu AH, Ziogas A, Tworoger SS, Schildkraut JM. Risk Prediction for Epithelial Ovarian Cancer in 11 United States–Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci. American Journal Of Epidemiology 2016, 184: 579-589. PMID: 27698005, PMCID: PMC5065620, DOI: 10.1093/aje/kww091.Peer-Reviewed Original ResearchConceptsEpidemiologic risk factorsEpithelial ovarian cancerYears of ageRisk factorsAbsolute riskOvarian cancerInvasive epithelial ovarian cancerCase-control studyOvarian Cancer Association ConsortiumHierarchical logistic regression modelsRisk prediction modelLogistic regression modelsProspective data setSignificant single nucleotide polymorphismsCase-control statusControl studyRisk predictionSingle nucleotide polymorphismsAgeCancerLow discriminatory powerWomenAUCRegression modelsNucleotide polymorphismsChronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium
Cannioto R, LaMonte MJ, Risch HA, Hong CC, Sucheston-Campbell LE, Eng KH, Szender JB, Chang-Claude J, Schmalfeldt B, Klapdor R, Gower E, Minlikeeva AN, Zirpoli GR, Bandera EV, Berchuck A, Cramer D, Doherty JA, Edwards RP, Fridley BL, Goode EL, Goodman MT, Hogdall E, Hosono S, Jensen A, Jordan S, Group O, Kjaer S, Matsuo K, Ness R, Olsen C, Olson S, Pearce C, Pike M, Rossing M, Szamreta E, Thompson P, Tseng C, Vierkant R, Webb P, Wentzensen N, Wicklund K, Winham S, Wu A, Modugno F, Schildkraut J, Terry K, Kelemen L, Moysich K. Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2016, 25: 1114-1124. PMID: 27197285, PMCID: PMC4930728, DOI: 10.1158/1055-9965.epi-15-1330.Peer-Reviewed Original ResearchConceptsRecreational physical inactivityRecreational physical activityPhysical inactivityEOC riskPooled analysisPhysical activityWeekly recreational physical activityLarge pooled analysisIndependent risk factorEpithelial ovarian cancer riskPhysical activity guidelinesBody mass indexMultivariable logistic regressionConfidence intervalsOvarian cancer riskOvarian Cancer Association ConsortiumDose of activityMenopausal statusChronic inactivityActivity guidelinesEOC patientsMass indexSignificant positive associationBody of evidenceIndependent associationAdult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study
Dixon SC, Nagle CM, Thrift AP, Pharoah PD, Pearce CL, Zheng W, Painter JN, Study A, Chenevix-Trench G, Fasching P, Beckmann M, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing M, Doherty J, Wicklund K, Chang-Claude J, Rudolph A, Moysich K, Odunsi K, Goodman M, Wilkens L, Thompson P, Shvetsov Y, Dörk T, Park-Simon T, Hillemanns P, Bogdanova N, Butzow R, Nevanlinna H, Pelttari L, Leminen A, Modugno F, Ness R, Edwards R, Kelley J, Heitz F, Karlan B, Kjær S, Høgdall E, Jensen A, Goode E, Fridley B, Cunningham J, Winham S, Giles G, Bruinsma F, Milne R, Southey M, Hildebrandt M, Wu X, Lu K, Liang D, Levine D, Bisogna M, Schildkraut J, Berchuck A, Cramer D, Terry K, Bandera E, Olson S, Salvesen H, Thomsen L, Kopperud R, Bjorge L, Kiemeney L, Massuger L, Pejovic T, Cook L, Le N, Swenerton K, Brooks-Wilson A, Kelemen L, Lubiński J, Huzarski T, Gronwald J, Menkiszak J, Wentzensen N, Brinton L, Yang H, Lissowska J, Høgdall C, Lundvall L, Song H, Tyrer J, Campbell I, Eccles D, Paul J, Glasspool R, Siddiqui N, Whittemore A, Sieh W, McGuire V, Rothstein J, Narod S, Phelan C, Risch H, McLaughlin J, Anton-Culver H, Ziogas A, Menon U, Gayther S, Ramus S, Gentry-Maharaj A, Wu A, Pike M, Tseng C, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzilowska A, Spiewankiewicz B, Webb P, Consortium O. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal Of Epidemiology 2016, 45: 884-895. PMID: 27401727, PMCID: PMC5644573, DOI: 10.1093/ije/dyw158.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAllelesBody Mass IndexFemaleGenetic MarkersGenome-Wide Association StudyGenotypeHumansLogistic ModelsMendelian Randomization AnalysisMeta-Analysis as TopicMiddle AgedMultivariate AnalysisObesityOvarian NeoplasmsPolymorphism, Single NucleotideRisk FactorsYoung AdultConceptsBody mass indexOvarian cancerSerous cancerMass indexOdds ratioObservational studyMendelian randomizationStudy-specific odds ratiosHigher body mass indexAdult body mass indexGrade serous ovarian cancerConfidence intervalsOvarian cancer riskOvarian Cancer Association ConsortiumSerous ovarian cancerWeighted genetic risk scoreLack of associationMendelian randomization studyGenetic risk scoreStrength of associationHistological subtypesRisk factorsCancer riskRisk scoreHGSC subtypeThe association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies
Præstegaard C, Kjaer SK, Nielsen TS, Jensen SM, Webb PM, Nagle CM, Høgdall E, Risch HA, Rossing MA, Doherty JA, Wicklund KG, Goodman MT, Modugno F, Moysich K, Ness RB, Edwards RP, Goode EL, Winham SJ, Fridley BL, Cramer DW, Terry KL, Schildkraut JM, Berchuck A, Bandera EV, Paddock L, Kiemeney LA, Massuger LF, Wentzensen N, Pharoah P, Song H, Whittemore AS, McGuire V, Sieh W, Rothstein J, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pearce CL, Pike MC, Lee AW, Chang-Claude J, Jensen A, Consortium O. The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiology 2016, 41: 71-79. PMID: 26851750, PMCID: PMC4993452, DOI: 10.1016/j.canep.2016.01.012.Peer-Reviewed Original ResearchConceptsBody mass indexAdvanced tumor stagePooled odds ratioTumor stageCase-control studyOvarian cancerOdds ratioSocioeconomic statusCigarette smokingPooled analysisPredictors of survivalEpithelial ovarian cancerConfidence intervalsSpecific odds ratiosRandom-effects modelObserved socioeconomic differencesLogistic regression modelsSES differencesDiagnostic delayMass indexDifferent histotypesCancer callsCancerDiagnosisSocioeconomic differencesRisk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma
McWilliams RR, Maisonneuve P, Bamlet WR, Petersen GM, Li D, Risch HA, Yu H, Fontham ET, Luckett B, Bosetti C, Negri E, La Vecchia C, Talamini R, de Mesquita H, Bracci P, Gallinger S, Neale RE, Lowenfels AB. Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma. Pancreas 2016, 45: 311-316. PMID: 26646264, PMCID: PMC4710562, DOI: 10.1097/mpa.0000000000000392.Peer-Reviewed Original ResearchConceptsEarly onset pancreatic cancerPancreatic cancerAge-dependent effectsRisk factorsFamily historySex-matched control subjectsDiagnosis of PCCase-control studyLogistic regression analysisPC patientsDiabetes mellitusAlcohol intakeControl subjectsOdds ratioPancreatic adenocarcinomaEarly onsetPatientsOlder adultsStrong associationObesitySmokingRegression analysisRiskAssociationComprehensive assessment
2015
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers
Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, EMBRACE, McGuffog L, Ellis S, Feng B, Buys S, Hopper J, Southey M, Tesoriero A, Investigators K, James P, Bruinsma F, Campbell I, Group A, Broeks A, Schmidt M, Hogervorst F, HEBON, Beckman M, Fasching P, Fletcher O, Johnson N, Sawyer E, Riboli E, Banerjee S, Menon U, Tomlinson I, Burwinkel B, Hamann U, Marme F, Rudolph A, Janavicius R, Tihomirova L, Tung N, Garber J, Cramer D, Terry K, Poole E, Tworoger S, Dorfling C, van Rensburg E, Godwin A, Guénel P, Truong T, Collaborators G, Stoppa-Lyonnet D, Damiola F, Mazoyer S, Sinilnikova O, Isaacs C, Maugard C, Bojesen S, Flyger H, Gerdes A, Hansen T, Jensen A, Kjaer S, Hogdall C, Hogdall E, Pedersen I, Thomassen M, Benitez J, González-Neira A, Osorio A, de la Hoya M, Segura P, Diez O, Lazaro C, Brunet J, Anton-Culver H, Eunjung L, John E, Neuhausen S, Ding Y, Castillo D, Weitzel J, Ganz P, Nussbaum R, Chan S, Karlan B, Lester J, Wu A, Gayther S, Ramus S, Sieh W, Whittermore A, Monteiro A, Phelan C, Terry M, Piedmonte M, Offit K, Robson M, Levine D, Moysich K, Cannioto R, Olson S, Daly M, Nathanson K, Domchek S, Lu K, Liang D, Hildebrant M, Ness R, Modugno F, Pearce L, Goodman M, Thompson P, Brenner H, Butterbach K, Meindl A, Hahnen E, Wappenschmidt B, Brauch H, Brüning T, Blomqvist C, Khan S, Nevanlinna H, Pelttari L, Aittomäki K, Butzow R, Bogdanova N, Dörk T, Lindblom A, Margolin S, Rantala J, Kosma V, Mannermaa A, Lambrechts D, Neven P, Claes K, Van Maerken T, Chang-Claude J, Flesch-Janys D, Heitz F, Varon-Mateeva R, Peterlongo P, Radice P, Viel A, Barile M, Peissel B, Manoukian S, Montagna M, Oliani C, Peixoto A, Teixeira M, Collavoli A, Hallberg E, Olson J, Goode E, Hart S, Shimelis H, Cunningham J, Giles G, Milne R, Healey S, Tucker K, Haiman C, Henderson B, Goldberg M, Tischkowitz M, Simard J, Soucy P, Eccles D, Le N, Borresen-Dale A, Kristensen V, Salvesen H, Bjorge L, Bandera E, Risch H, Zheng W, Beeghly-Fadiel A, Cai H, Pylkäs K, Tollenaar R, van der Ouweland A, Andrulis I, Knight J, OCGN, Narod S, Devilee P, Winqvist R, Figueroa J, Greene M, L. P, Loud J, García-Closas M, Schoemaker M, Czene K, Darabi H, McNeish I, Siddiquil N, Glasspool R, Kwong A, Park S, Teo S, Yoon S, Matsuo K, Hosono S, Woo Y, Gao Y, Foretova L, Singer C, Rappaport-Feurhauser C, Friedman E, Laitman Y, Rennert G, Imyanitov E, Hulick P, Olopade O, Senter L, Olah E, Doherty J, Schildkraut J, Koppert L, Kiemeney L, Massuger L, Cook L, Pejovic T, Li J, Borg A, Öfverholm A, Rossing M, Wentzensen N, Henriksson K, Cox A, Cross S, Pasini B, Shah M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Gronwald J, Agnarsson B, Kupryjanczyk J, Moes-Sosnowska J, Fostira F, Konstantopoulou I, Slager S, Jones M, in the genome P, Antoniou A, Berchuck A, Swerdlow A, Chenevix-Trench G, Dunning A, Pharoah P, Hall P, Easton D, Couch F, Spurdle A, Goldgar D. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal Of The National Cancer Institute 2015, 108: djv315. PMID: 26586665, PMCID: PMC4907358, DOI: 10.1093/jnci/djv315.Peer-Reviewed Original ResearchConceptsOvarian cancerBreast cancerVariant carriersCancer riskEstrogen receptor-negative breast cancerReceptor-negative breast cancerCancer case patientsInvasive ovarian cancerHormone-related cancersProstate cancer riskConfidence intervalsOvarian cancer riskSignificant inverse associationCox proportional hazardsSerous ovarian cancerRisk of breastBRCA1 mutation carriersPathogenic BRCA2 variantsControl patientsCase patientsInverse associationOdds ratioProstate cancerMutation carriersProportional hazardsDietary flavonoid intake and Barrett's esophagus in western Washington State
Petrick JL, Steck SE, Bradshaw PT, Chow WH, Engel LS, He K, Risch HA, Vaughan TL, Gammon MD. Dietary flavonoid intake and Barrett's esophagus in western Washington State. Annals Of Epidemiology 2015, 25: 730-735.e2. PMID: 26169148, PMCID: PMC4567908, DOI: 10.1016/j.annepidem.2015.05.010.Peer-Reviewed Original ResearchConceptsOdds of BESpecialized intestinal metaplasiaBarrett's esophagusOdds ratioIntestinal metaplasiaInverse associationPrecursor lesionsWestern Washington StateDietary flavonoid intakeDecreased odds ratioFood frequency questionnaireAdequate dietary intakeBody mass indexCase-control investigationCancer precursor lesionsCase-control study participantsDietary sourcesLogistic regression modelsFlavonoid classesMain dietary sourceAnthocyanidin intakeFrequency questionnaireFlavonoid intakeMass indexIsoflavone intakeInfertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2)
Yang HP, Cook LS, Weiderpass E, Adami HO, Anderson KE, Cai H, Cerhan JR, Clendenen TV, Felix AS, Friedenreich CM, Garcia-Closas M, Goodman MT, Liang X, Lissowska J, Lu L, Magliocco AM, McCann SE, Moysich KB, Olson SH, Petruzella S, Pike MC, Polidoro S, Ricceri F, Risch HA, Sacerdote C, Setiawan VW, Shu XO, Spurdle AB, Trabert B, Webb PM, Wentzensen N, Xiang YB, Xu Y, Yu H, Zeleniuch-Jacquotte A, Brinton LA. Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). British Journal Of Cancer 2015, 112: 925-933. PMID: 25688738, PMCID: PMC4453954, DOI: 10.1038/bjc.2015.24.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskCancer riskInfertility causesOdds ratioElevated endometrial cancer riskEndometrial cancer risk factorsEndometrial Cancer ConsortiumSelf-reported infertilityAdjusted odds ratioCancer risk factorsConfidence intervalsCase-control studyStudy-specific definitionsParous womenEndometrial cancerNulliparous womenPooled analysisNational registryRisk factorsCancer ConsortiumInfertilityNulliparityInfertility concernsInfertility dataLarger study
2014
Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study
Lee AW, Tyrer JP, Doherty JA, Stram DA, Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Spiewankiewicz B, Myers EJ, Study A, Group A, Chenevix-Trench G, Fasching PA, Beckmann MW, Ekici AB, Hein A, Vergote I, Van Nieuwenhuysen E, Lambrechts D, Wicklund KG, Eilber U, Wang-Gohrke S, Chang-Claude J, Rudolph A, Sucheston-Campbell L, Odunsi K, Moysich KB, Shvetsov YB, Thompson PJ, Goodman MT, Wilkens LR, Dörk T, Hillemanns P, Dürst M, Runnebaum IB, Bogdanova N, Pelttari LM, Nevanlinna H, Leminen A, Edwards RP, Kelley JL, Harter P, Schwaab I, Heitz F, du Bois A, Orsulic S, Lester J, Walsh C, Karlan BY, Hogdall E, Kjaer SK, Jensen A, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Southey MC, Giles GG, Bruinsma F, Wu X, Hildebrandt MA, Lu K, Liang D, Bisogna M, Levine DA, Weber RP, Schildkraut JM, Iversen ES, Berchuck A, Terry KL, Cramer DW, Tworoger SS, Poole EM, Olson SH, Orlow I, Bandera EV, Bjorge L, Tangen IL, Salvesen HB, Krakstad C, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Bean Y, Pejovic T, Kellar M, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Lubinski J, Gronwald J, Cybulski C, Jakubowska A, Wentzensen N, Brinton LA, Lissowska J, Yang H, Nedergaard L, Lundvall L, Hogdall C, Song H, Campbell IG, Eccles D, Glasspool R, Siddiqui N, Carty K, Paul J, McNeish IA, Sieh W, McGuire V, Rothstein JH, Whittemore AS, McLaughlin JR, Risch HA, Phelan CM, Anton-Culver H, Ziogas A, Menon U, Ramus SJ, Gentry-Maharaj A, Harrington P, Pike MC, Modugno F, Rossing MA, Ness RB, Pharoah PD, Stram DO, Wu AH, Pearce CL. Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology 2014, 136: 542-548. PMID: 25528498, PMCID: PMC4892108, DOI: 10.1016/j.ygyno.2014.12.017.Peer-Reviewed Original ResearchConceptsOvarian cancer riskOvarian Cancer StudyCancer riskGene-level associationsOnly modest associationsUnconditional logistic regressionCancer studiesHormone-related diseasesPathway genesGonadotropin hypothesisEtiologic roleGenome-wide significant associationOvarian cancerProstate cancerLarger sample sizeGonadotropinSignificant associationDisease riskModest associationLogistic regressionGene-level testsHigh-penetrance susceptibility genesCandidate gene studiesStrong genetic basisUnderstanding of biologyGastroesophageal Reflux in Relation to Adenocarcinomas of the Esophagus: A Pooled Analysis from the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON)
Cook MB, Corley DA, Murray LJ, Liao LM, Kamangar F, Ye W, Gammon MD, Risch HA, Casson AG, Freedman ND, Chow WH, Wu AH, Bernstein L, Nyrén O, Pandeya N, Whiteman DC, Vaughan TL. Gastroesophageal Reflux in Relation to Adenocarcinomas of the Esophagus: A Pooled Analysis from the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON). PLOS ONE 2014, 9: e103508. PMID: 25075959, PMCID: PMC4116205, DOI: 10.1371/journal.pone.0103508.Peer-Reviewed Original ResearchConceptsEsophagogastric junction adenocarcinomaBody mass indexRegurgitation symptomsEsophageal adenocarcinomaEsophageal Adenocarcinoma ConsortiumGastroesophageal refluxCigarette smokingMass indexMultivariable logistic regressionFrequency of symptomsMajor risk factorCase-control studyHeartburn durationSymptom durationJunction adenocarcinomaPooled analysisRisk factorsCancer sitesOdds ratioStratified analysisHigh riskSummary estimatesSignificant associationSymptomsLogistic regressionAspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium
Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ, Group T, Risch H, Rossing M, Doherty J, Goodman M, Lurie G, Kjær S, Hogdall E, Jensen A, Cramer D, Terry K, Vitonis A, Bandera E, Olson S, King M, Chandran U, Anton-Culver H, Ziogas A, Menon U, Gayther S, Ramus S, Gentry-Maharaj A, Wu A, Pearce C, Pike M, Berchuck A, Schildkraut J, Wentzensen N, Consortium O. Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal Of The National Cancer Institute 2014, 106: djt431. PMID: 24503200, PMCID: PMC3924755, DOI: 10.1093/jnci/djt431.Peer-Reviewed Original ResearchMeSH KeywordsAcetaminophenAnti-Inflammatory Agents, Non-SteroidalAnticarcinogenic AgentsAspirinAustraliaCarcinoma, Ovarian EpithelialCase-Control StudiesData CollectionDenmarkDrug Administration ScheduleFemaleHumansIncidenceLogistic ModelsNeoplasms, Glandular and EpithelialOdds RatioOvarian NeoplasmsProtective AgentsRiskUnited KingdomUnited StatesConceptsNonaspirin nonsteroidal anti-inflammatory drugsNonaspirin NSAIDsInvasive epithelial ovarian cancerNonsteroidal anti-inflammatory drugsLow-dose aspirinEpithelial ovarian cancerOvarian cancerAnti-inflammatory drugsAspirin useAcetaminophen useOdds ratioPopulation-based case-control studyDaily aspirin usersRegular aspirin useOvarian cancer riskCase-control studyOvarian Cancer Association ConsortiumHigh-dose usageDose of useAspirin regimenAnalgesic useAspirin usersCardiovascular eventsDose aspirinCase patientsCigarette smoking and pancreatic cancer risk: More to the story than just pack-years
Schulte A, Pandeya N, Tran B, Fawcett J, Fritschi L, Risch HA, Webb PM, Whiteman DC, Neale RE, Group Q. Cigarette smoking and pancreatic cancer risk: More to the story than just pack-years. European Journal Of Cancer 2014, 50: 997-1003. PMID: 24461200, DOI: 10.1016/j.ejca.2013.12.014.Peer-Reviewed Original ResearchConceptsPancreatic cancer riskCigarette smokingOdds ratioPancreatic adenocarcinomaCancer riskAustralian population-based case-control studyPopulation-based case-control studyLogistic regressionPancreatic cancer patientsConfidence intervalsCase-control studyPancreatic cancer studiesCurrent smokersAlcohol intakeSmoking patternsCancer patientsPancreatic cancerRisk factorsSmoking componentSmokingDisease riskRisk estimatesCancer studiesSmokersAdenocarcinoma